Prolonged standard treatment for systemic lupus erythematosus fails to normalize the secretion of innate immunity-related chemokines

European Cytokine Network

Volumn 21, Issue 1, 2010, Pages 71-76

  Vega, Luisa ^a   Barbado, Julia ^a   Almansa, Raquel ^a   González Gallego, Rocío ^a   Rico, Lucía ^a   Jimeno, Antonio ^a   Nocito, Mercedes ^a   De Lejarazu, Raúl Ortiz ^a   Bermejo Martin, Jesus F ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Chemokines; Cytokines; Interferons; Lupus; Profiles

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CELECOXIB; CHEMOKINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFLAZACORT; ETORICOXIB; GAMMA INTERFERON; GROWTH FACTOR; HYDROXYCHLOROQUINE; INDOMETACIN; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PLASMA; REMISSION; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; TISSUE INJURY; TREATMENT DURATION;

EID: 77149178446     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0176     Document Type: Article

References (23)

1. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098.
2. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173: 310.
3. Crow MK, Kirou KA. Interferon-induced versus chemokine transcripts as lupus biomarkers. Arthritis Res Ther 2008; 10: 126.
4. Vilá LM,MolinaMJ, Mayor AM, Cruz JJ, Ríos-Olivares E, Ríos Z. Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 2007; 26: 718-22.
5. Fu Q, Chen X, Cui H, et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008; 10: R112.
6. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-4.
7. AringerM,GraningerWB, SteinerG, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161.
8. Mellor-Pita S, Citores MJ, Castejon R, et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009; 76B: 261-70.
9. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393.
10. Robak E, Robak T,WozniackaA, Zak-PrelichM, Sysa-Jedrzejowska A. Stepien Proinflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw 2002; 13: 364.
11. Nalbandian A, Crispín JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157: 209-15.
12. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385.
13. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 519.
14. Rahman A. Cytokines in systemic lupus erythematosus, London, UK. Arthritis Research & Therapy 2003; 5: 160.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271.
16. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288.
17. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363.
18. Hornung F, Scala G, Lenardo MJ. TNF-alpha-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes. J Immunol 2000; 15: 6180.
19. Willeke P, Schlüter B, Schotte H, et al. Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption. Lupus 2004; 13: 257.
20. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with clinical and serological manifestations of systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1692.
21. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008 28; 358: 929.
22. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303.
23. Mirolo M, Fabbri M, Sironi M, et al. Impact of the antiinflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 2008; 19: 119.